Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 400
Healthy volunteers: no

Brief summary:
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.

Detailed description:

Arms:
arm 1: Liraglutide 0.9 mg + glibenclamide placebo arm 2: Glibenclamide 1.25-2.5 mg + liraglutide placebo

Interventions: intervention 1: liraglutide intervention 2: glibenclamide intervention 3: placebo intervention 4: placebo
Intervention descriptions: intervention 1: 0.9 mg/day. Injected s.c. (under the skin) once daily. intervention 2: 1.25-2.5 mg tablet. Given orally once or twice daily. intervention 3: liraglutide placebo. Injected s.c. (under the skin) once daily. intervention 4: glibenclamide placebo. Given orally once or twice daily.

Protocol document: